Shares of Phreesia, Inc. (PHR) surged 5.00% in Thursday's intraday trading session, following a series of analyst actions that painted a largely positive picture for the healthcare technology company. The stock's upward movement was primarily fueled by Truist Securities' decision to raise its price target, coupled with maintained buy ratings from multiple firms.
Truist Securities, a key player in shaping investor sentiment, raised its price target for Phreesia from $34 to $35 while maintaining a Buy rating on the stock. The firm cited the company's improved outlook as the basis for this upward revision. Additionally, Canaccord Genuity reaffirmed its Buy rating on Phreesia, further bolstering investor confidence.
However, it wasn't all positive news for Phreesia. Citigroup slightly tempered expectations by reducing its target price from $35 to $33. Despite this, the overall analyst consensus remains bullish, with FactSet reporting an average rating of Buy and a mean price target of $31.43 for Phreesia. The mixed but generally positive analyst actions appear to have tipped the scales in favor of the bulls, driving the stock's significant intraday gain.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。